Limits...
Pantoprazole decreases cell viability and function of human osteoclasts in vitro.

Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT - Mediators Inflamm. (2015)

Bottom Line: Proton pump inhibitors (PPIs) are commonly prescribed drugs that decrease stomach acidity and are thus often used to treat gastroesophageal reflux disease and as a preventative agent for the adverse effects of nonsteroidal anti-inflammatory drugs on the stomach mucosa.Osteoclast-specific gene expression was evaluated after seven days and revealed no significant differences between all samples.Overall, the bone degrading and resorptive function of osteoclasts is inhibited by the administration of proton pump inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Experimental Trauma Surgery, Department of Trauma Surgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Straße 22, 81675 Munich, Germany.

ABSTRACT
Proton pump inhibitors (PPIs) are commonly prescribed drugs that decrease stomach acidity and are thus often used to treat gastroesophageal reflux disease and as a preventative agent for the adverse effects of nonsteroidal anti-inflammatory drugs on the stomach mucosa. In recently published literature, an association between proton pump inhibitor administration and increased fracture risk has been stated. In order to reveal the underlying pathomechanisms of these observations, the effects of pantoprazole, a representative of the proton pump inhibitors, on human osteoclasts in vitro were evaluated in this study. Osteoclasts were stimulated with increasing concentrations of pantoprazole ranging from 0 μg/mL to 10 μg/mL over a period of seven days. Cell viability and tartrate-resistant acid phosphatase (TRAP) activity assays were performed after 1 day, 3 days, and 7 days, respectively. Here, stimulated osteoclasts presented a significantly lower viability and TRAP activity than the negative controls. Osteoclast-specific gene expression was evaluated after seven days and revealed no significant differences between all samples. Overall, the bone degrading and resorptive function of osteoclasts is inhibited by the administration of proton pump inhibitors. While PPI-related fractures through "basic multicellular unit" dysfunction are unlikely, the underlying pathomechanism remains unknown.

No MeSH data available.


Related in: MedlinePlus

A resorption lacuna is made visible on the dentine chip through toluidine blue staining. The picture was taken under light microscopy at 10x magnification, 7 days after differentiation. The sample in this picture consisted of osteoclasts that were not stimulated with pantoprazole.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4385676&req=5

fig2: A resorption lacuna is made visible on the dentine chip through toluidine blue staining. The picture was taken under light microscopy at 10x magnification, 7 days after differentiation. The sample in this picture consisted of osteoclasts that were not stimulated with pantoprazole.

Mentions: The stainings were performed on negative control samples of each donor 7 days after completed differentiation. The von Kossa-stained samples show that the differentiated cells actively resorbed calcium phosphate (Figures 1(a) and 1(b)) while the exemplary toluidine blue-stained dentine chip shows the formation of Howship's lacuna (Figure 2). Furthermore, the strong accumulation of TRAP stain in the depicted cells suggests successful differentiation of the PBMCs into active osteoclasts after days 1, 3, and 7 after differentiation (Figures 3(a), 3(b), and 3(c)).


Pantoprazole decreases cell viability and function of human osteoclasts in vitro.

Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT - Mediators Inflamm. (2015)

A resorption lacuna is made visible on the dentine chip through toluidine blue staining. The picture was taken under light microscopy at 10x magnification, 7 days after differentiation. The sample in this picture consisted of osteoclasts that were not stimulated with pantoprazole.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4385676&req=5

fig2: A resorption lacuna is made visible on the dentine chip through toluidine blue staining. The picture was taken under light microscopy at 10x magnification, 7 days after differentiation. The sample in this picture consisted of osteoclasts that were not stimulated with pantoprazole.
Mentions: The stainings were performed on negative control samples of each donor 7 days after completed differentiation. The von Kossa-stained samples show that the differentiated cells actively resorbed calcium phosphate (Figures 1(a) and 1(b)) while the exemplary toluidine blue-stained dentine chip shows the formation of Howship's lacuna (Figure 2). Furthermore, the strong accumulation of TRAP stain in the depicted cells suggests successful differentiation of the PBMCs into active osteoclasts after days 1, 3, and 7 after differentiation (Figures 3(a), 3(b), and 3(c)).

Bottom Line: Proton pump inhibitors (PPIs) are commonly prescribed drugs that decrease stomach acidity and are thus often used to treat gastroesophageal reflux disease and as a preventative agent for the adverse effects of nonsteroidal anti-inflammatory drugs on the stomach mucosa.Osteoclast-specific gene expression was evaluated after seven days and revealed no significant differences between all samples.Overall, the bone degrading and resorptive function of osteoclasts is inhibited by the administration of proton pump inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Experimental Trauma Surgery, Department of Trauma Surgery, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Straße 22, 81675 Munich, Germany.

ABSTRACT
Proton pump inhibitors (PPIs) are commonly prescribed drugs that decrease stomach acidity and are thus often used to treat gastroesophageal reflux disease and as a preventative agent for the adverse effects of nonsteroidal anti-inflammatory drugs on the stomach mucosa. In recently published literature, an association between proton pump inhibitor administration and increased fracture risk has been stated. In order to reveal the underlying pathomechanisms of these observations, the effects of pantoprazole, a representative of the proton pump inhibitors, on human osteoclasts in vitro were evaluated in this study. Osteoclasts were stimulated with increasing concentrations of pantoprazole ranging from 0 μg/mL to 10 μg/mL over a period of seven days. Cell viability and tartrate-resistant acid phosphatase (TRAP) activity assays were performed after 1 day, 3 days, and 7 days, respectively. Here, stimulated osteoclasts presented a significantly lower viability and TRAP activity than the negative controls. Osteoclast-specific gene expression was evaluated after seven days and revealed no significant differences between all samples. Overall, the bone degrading and resorptive function of osteoclasts is inhibited by the administration of proton pump inhibitors. While PPI-related fractures through "basic multicellular unit" dysfunction are unlikely, the underlying pathomechanism remains unknown.

No MeSH data available.


Related in: MedlinePlus